董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erin M. Lavelle | 女 | Independent Director | 48 | 21.24万美元 | 6.91 | 2025-11-14 |
| Chris Cain | 男 | Independent Director | 41 | 20.57万美元 | 2.30 | 2025-11-14 |
| Tomas Kiselak | 男 | Independent Director | 39 | 20.63万美元 | 1118.31 | 2025-11-14 |
| Tom Frohlich | 男 | Chief Executive Officer and Director | 50 | 979.98万美元 | 93.20 | 2025-11-14 |
| Tomas Kiselak | 男 | Independent Director | 39 | 未披露 | 未持股 | 2025-11-14 |
| Lawrence Otto Klein | 男 | Independent Director | 43 | 21.01万美元 | 12.45 | 2025-11-14 |
| Eric L. Dobmeier | 男 | Chair and Independent Director | 57 | 22.69万美元 | 11.32 | 2025-11-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bradford Dahms | 男 | Chief Financial Officer and Treasurer | 37 | 413.20万美元 | 未持股 | 2025-11-14 |
| Tom Frohlich | 男 | Chief Executive Officer and Director | 50 | 979.98万美元 | 93.20 | 2025-11-14 |
| Andrew James King | 男 | Chief Scientific Officer and Head of Research & Development | 46 | 454.18万美元 | 68.04 | 2025-11-14 |
| Elizabeth Balta | 女 | Corporate Secretary and General Counsel | 55 | 未披露 | 未持股 | 2025-11-14 |
董事简历
中英对照 | 中文 | 英文- Erin M. Lavelle
-
Erin M.Lavelle自2020年10月起担任我们的执行副总裁、首席运营官和首席财务官。在加入Eliem之前，Lavelle女士于2018年4月至2020年2月担任Alder的首席运营官，此前该公司被H.Lundbeck收购。2017年10月至2018年3月，Lavelle女士担任Amgen台湾分公司总经理。2016年6月至2017年9月，Lavelle女士担任安进公司日本和亚太卓越商业和数字健康执行董事。从2003年7月到2016年6月，Lavelle女士在Amgen担任越来越多的职务，包括担任Amgen’；在全球营销、全球商业金融、战略和企业发展领域的执行董事。她的职业生涯始于1998年，担任Merrill Lynch&Co.医疗保健部门的投资银行家。Lavelle女士目前在NeoleukinTherapeutics，Inc.的董事会任职。Lavelle女士拥有耶鲁大学经济学学士学位。
Erin M. Lavelle has served as a member of Board since September 2024. From October 2023 until July 2024, Ms. Lavelle served as the Chief Operating Officer and Chief Financial Officer at ProfoundBio, Inc., a private biotechnology company that was acquired by Genmab A/S in May 2024. Prior to ProfoundBio, Ms. Lavelle served as Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) (Nasdaq: CLYM), a biotechnology company, from October 2020 to March 2023. From April 2018 to February 2020, Ms. Lavelle served as the Chief Operating Officer at Alder BioPharmaceuticals, Inc., a Nasdaq listed biotechnology company that was acquired by H. Lundbeck A/S in October 2019. In addition to that role, she served as Alder's appointed director for Vitaeris Inc., a privately held biotechnology company based in Vancouver, British Columbia, Canada. Prior to that, Ms. Lavelle served in vario roles at Amgen Inc. (Nasdaq: AMGN) from 2003 to 2018, most recently serving as General Manager Taiwan from September 2017 to April 2018, as Executive Director, Japan Asia Pacific (Hong Kong) from May 2016 to September 2017, and Executive Director, Global Marketing Biness Analytics and Insights from June 2014 to May 2016. She started her career as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle currently serves as a member of the board of directors of Avalyn Pharma Inc., Aviceda Therapeutics, Inc., Expedition Therapeutics Inc. and Riv Pharmaceuticals, Inc., including audit chair of Avalyn and Riv, and served as a member of the board of directors of Neoleukin Therapeutics, Inc., a Nasdaq listed biopharmaceutical company, which later became Neurogene Inc. (Nasdaq: NGNE), from May 2020 to December 2023. Ms. Lavelle holds a Bachelor of Arts in Economics from Yale University. - Erin M.Lavelle自2020年10月起担任我们的执行副总裁、首席运营官和首席财务官。在加入Eliem之前，Lavelle女士于2018年4月至2020年2月担任Alder的首席运营官，此前该公司被H.Lundbeck收购。2017年10月至2018年3月，Lavelle女士担任Amgen台湾分公司总经理。2016年6月至2017年9月，Lavelle女士担任安进公司日本和亚太卓越商业和数字健康执行董事。从2003年7月到2016年6月，Lavelle女士在Amgen担任越来越多的职务，包括担任Amgen’；在全球营销、全球商业金融、战略和企业发展领域的执行董事。她的职业生涯始于1998年，担任Merrill Lynch&Co.医疗保健部门的投资银行家。Lavelle女士目前在NeoleukinTherapeutics，Inc.的董事会任职。Lavelle女士拥有耶鲁大学经济学学士学位。
- Erin M. Lavelle has served as a member of Board since September 2024. From October 2023 until July 2024, Ms. Lavelle served as the Chief Operating Officer and Chief Financial Officer at ProfoundBio, Inc., a private biotechnology company that was acquired by Genmab A/S in May 2024. Prior to ProfoundBio, Ms. Lavelle served as Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) (Nasdaq: CLYM), a biotechnology company, from October 2020 to March 2023. From April 2018 to February 2020, Ms. Lavelle served as the Chief Operating Officer at Alder BioPharmaceuticals, Inc., a Nasdaq listed biotechnology company that was acquired by H. Lundbeck A/S in October 2019. In addition to that role, she served as Alder's appointed director for Vitaeris Inc., a privately held biotechnology company based in Vancouver, British Columbia, Canada. Prior to that, Ms. Lavelle served in vario roles at Amgen Inc. (Nasdaq: AMGN) from 2003 to 2018, most recently serving as General Manager Taiwan from September 2017 to April 2018, as Executive Director, Japan Asia Pacific (Hong Kong) from May 2016 to September 2017, and Executive Director, Global Marketing Biness Analytics and Insights from June 2014 to May 2016. She started her career as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle currently serves as a member of the board of directors of Avalyn Pharma Inc., Aviceda Therapeutics, Inc., Expedition Therapeutics Inc. and Riv Pharmaceuticals, Inc., including audit chair of Avalyn and Riv, and served as a member of the board of directors of Neoleukin Therapeutics, Inc., a Nasdaq listed biopharmaceutical company, which later became Neurogene Inc. (Nasdaq: NGNE), from May 2020 to December 2023. Ms. Lavelle holds a Bachelor of Arts in Economics from Yale University.
- Chris Cain
-
Chris Cain自2020年7月起担任我们的董事会成员，是医疗保健投资基金Fairmount Funds Management LLC“Fairmount Funds”的指定人。Cain博士自2020年4月以来一直担任Fairmount Funds的研究总监。从2019年2月至2020年2月，Cain博士担任专注于生物治疗的风险投资基金Samsara Biocapital的副总裁。在担任该职位之前，该隐博士于2016年7月至2019年1月在专注于生命科学的风险投资基金Apple Tree Partners任职，最近担任高级合伙人。Cain博士于2014年11月至2016年5月担任投资管理公司RA Capital Management的合伙人。在此之前，Cain博士于2010年6月至2014年10月在BioCentury Publications任职，最近担任副主编。他在加州大学圣巴巴拉分校获得文学士学位，在加州大学旧金山分校获得生物化学和分子生物学博士学位。
Chris Cain has served as a member of Board since July 2024. Dr. Cain has served as Director of Research at Fairmount Funds Management LLC, a healthcare investment firm, since April 2020. Prior to Fairmount, Dr. Cain served in vario positions, his most recent being Vice President, at healthcare funds, including Samsara BioCapital, LP, a biotherapeutics foced venture capital fund, from February 2019 to February 2020, Apple Tree Partners, a life sciences foced venture capital fund, from 2016 to January 2019, and, before that, RA Capital Management, an investment management company, where he invested in both public and emerging private biotechnology companies. Previoly, Dr. Cain was a writer and editor at BioCentury Publications. He currently serves as a member of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT), Viridian Therapeutics Inc. (Nasdaq: VRDN) and Galecto Inc. (Nasdaq: GLTO). He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco. - Chris Cain自2020年7月起担任我们的董事会成员，是医疗保健投资基金Fairmount Funds Management LLC“Fairmount Funds”的指定人。Cain博士自2020年4月以来一直担任Fairmount Funds的研究总监。从2019年2月至2020年2月，Cain博士担任专注于生物治疗的风险投资基金Samsara Biocapital的副总裁。在担任该职位之前，该隐博士于2016年7月至2019年1月在专注于生命科学的风险投资基金Apple Tree Partners任职，最近担任高级合伙人。Cain博士于2014年11月至2016年5月担任投资管理公司RA Capital Management的合伙人。在此之前，Cain博士于2010年6月至2014年10月在BioCentury Publications任职，最近担任副主编。他在加州大学圣巴巴拉分校获得文学士学位，在加州大学旧金山分校获得生物化学和分子生物学博士学位。
- Chris Cain has served as a member of Board since July 2024. Dr. Cain has served as Director of Research at Fairmount Funds Management LLC, a healthcare investment firm, since April 2020. Prior to Fairmount, Dr. Cain served in vario positions, his most recent being Vice President, at healthcare funds, including Samsara BioCapital, LP, a biotherapeutics foced venture capital fund, from February 2019 to February 2020, Apple Tree Partners, a life sciences foced venture capital fund, from 2016 to January 2019, and, before that, RA Capital Management, an investment management company, where he invested in both public and emerging private biotechnology companies. Previoly, Dr. Cain was a writer and editor at BioCentury Publications. He currently serves as a member of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT), Viridian Therapeutics Inc. (Nasdaq: VRDN) and Galecto Inc. (Nasdaq: GLTO). He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco.
- Tomas Kiselak
-
Tomas Kiselak自2024年11月起担任Korsana董事会成员。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是他于2016年4月共同创立的一家医疗投资公司。在加入Fairmount之前，他是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2020年10月起担任Viridian的董事会成员，并自2023年6月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO）的董事，自2023年6月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE），自2020年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。
Tomas Kiselak has served as a member of the Korsana board of directors since November 2024. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, he was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and has been a member of Viridian's board since October 2020, and has served as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since June 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since June 2023, Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2020, and several private companies. Mr. Kiselak previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 until March 2025. He received a B.S. in Neuroscience and Economics from Amherst College. - Tomas Kiselak自2024年11月起担任Korsana董事会成员。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是他于2016年4月共同创立的一家医疗投资公司。在加入Fairmount之前，他是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2020年10月起担任Viridian的董事会成员，并自2023年6月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO）的董事，自2023年6月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE），自2020年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。
- Tomas Kiselak has served as a member of the Korsana board of directors since November 2024. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, he was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and has been a member of Viridian's board since October 2020, and has served as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since June 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since June 2023, Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2020, and several private companies. Mr. Kiselak previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 until March 2025. He received a B.S. in Neuroscience and Economics from Amherst College.
- Tom Frohlich
-
Tom Frohlich自2024年10月起担任首席执行官和董事会成员。从2021年6月至2023年10月，Frohlich先生担任首席运营官，并于2019年1月至2021年6月在Chinook Therapeutics, Inc.担任首席必利官，该公司是一家在纳斯达克上市的生物制药公司，于2023年8月被诺华公司收购，负责战略、必利客开发、商业规划、化学、制造和控制、质量和项目管理。从2018年4月到2023年10月，Frohlich先生还在医疗保健投资公司Versant Ventures担任运营负责人，随后担任常驻企业家，负责公司创建和尽职调查。2018年4月至2018年12月，Frohlich先生在Inception Sciences，Inc.担任Biness Development高级副总裁，Inception Sciences，Inc.是一家与Versant Ventures共同创立的药物发现引擎。在加入Inception Sciences之前，2014年至2018年，Frohlich先生在生物制药公司Arbut Biopharma（前身为Tekmira Pharmaceuticals）（纳斯达克：AB）担任越来越重要的职务，最近一次是在2016年至2018年担任必宁发展副总裁。在加入Arbut Biopharma之前，Frohlich先生于2007年至2014年在制药和医疗技术公司强生（NYSE：JNJ）从事国际工作，并于1998年至2006年在制药公司默克制药公司（NYSE：MRK）从事领导产品开发各个阶段的商业战略的各种职务。Frohlich先生担任Nested Therapeutics和Borealis Biosciences的董事会成员。Frohlich先生获得维多利亚大学生物化学学士学位和牛津大学工商管理硕士学位。
Tom Frohlich has served as Chief Executive Officer and as a member of Board since October 2024. From June 2021 to October 2023, Mr. Frohlich served as Chief Operating Officer and, from January 2019 to June 2021, as Chief Biness Officer at Chinook Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Novartis AG in Augt 2023, where he was responsible for strategy, biness development, commercial planning, chemistry, manufacturing and controls, quality and program management. From April 2018 to October 2023, Mr. Frohlich also served as an Operating Principal and subsequently as an Entrepreneur in Residence at Versant Ventures, a healthcare investment firm, where he was responsible for company creation and due diligence. From April 2018 to December 2018, Mr. Frohlich served as the Senior Vice President of Biness Development at Inception Sciences, Inc., a drug discovery engine co founded with Versant Ventures. Prior to joining Inception Sciences, from 2014 to 2018, Mr. Frohlich held positions of increasing responsibility at Arbut Biopharma (formerly Tekmira Pharmaceuticals) (Nasdaq: AB), a biopharmaceutical company, most recently as Vice President of Biness Development from 2016 through 2018. Prior to joining Arbut Biopharma, Mr. Frohlich worked internationally at Johnson & Johnson (NYSE: JNJ), a pharmaceutical and medical technology company, from 2007 through 2014, and at Merck & Co., Inc. (NYSE: MRK), a pharmaceutical company, from 1998 through 2006, in vario roles leading commercial strategy across all stages of product development. Mr. Frohlich serves on the board of directors of Nested Therapeutics and Borealis Biosciences. Mr. Frohlich received a B.Sc. in Biochemistry from the University of Victoria and an M.B.A. from the University of Oxford. - Tom Frohlich自2024年10月起担任首席执行官和董事会成员。从2021年6月至2023年10月，Frohlich先生担任首席运营官，并于2019年1月至2021年6月在Chinook Therapeutics, Inc.担任首席必利官，该公司是一家在纳斯达克上市的生物制药公司，于2023年8月被诺华公司收购，负责战略、必利客开发、商业规划、化学、制造和控制、质量和项目管理。从2018年4月到2023年10月，Frohlich先生还在医疗保健投资公司Versant Ventures担任运营负责人，随后担任常驻企业家，负责公司创建和尽职调查。2018年4月至2018年12月，Frohlich先生在Inception Sciences，Inc.担任Biness Development高级副总裁，Inception Sciences，Inc.是一家与Versant Ventures共同创立的药物发现引擎。在加入Inception Sciences之前，2014年至2018年，Frohlich先生在生物制药公司Arbut Biopharma（前身为Tekmira Pharmaceuticals）（纳斯达克：AB）担任越来越重要的职务，最近一次是在2016年至2018年担任必宁发展副总裁。在加入Arbut Biopharma之前，Frohlich先生于2007年至2014年在制药和医疗技术公司强生（NYSE：JNJ）从事国际工作，并于1998年至2006年在制药公司默克制药公司（NYSE：MRK）从事领导产品开发各个阶段的商业战略的各种职务。Frohlich先生担任Nested Therapeutics和Borealis Biosciences的董事会成员。Frohlich先生获得维多利亚大学生物化学学士学位和牛津大学工商管理硕士学位。
- Tom Frohlich has served as Chief Executive Officer and as a member of Board since October 2024. From June 2021 to October 2023, Mr. Frohlich served as Chief Operating Officer and, from January 2019 to June 2021, as Chief Biness Officer at Chinook Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Novartis AG in Augt 2023, where he was responsible for strategy, biness development, commercial planning, chemistry, manufacturing and controls, quality and program management. From April 2018 to October 2023, Mr. Frohlich also served as an Operating Principal and subsequently as an Entrepreneur in Residence at Versant Ventures, a healthcare investment firm, where he was responsible for company creation and due diligence. From April 2018 to December 2018, Mr. Frohlich served as the Senior Vice President of Biness Development at Inception Sciences, Inc., a drug discovery engine co founded with Versant Ventures. Prior to joining Inception Sciences, from 2014 to 2018, Mr. Frohlich held positions of increasing responsibility at Arbut Biopharma (formerly Tekmira Pharmaceuticals) (Nasdaq: AB), a biopharmaceutical company, most recently as Vice President of Biness Development from 2016 through 2018. Prior to joining Arbut Biopharma, Mr. Frohlich worked internationally at Johnson & Johnson (NYSE: JNJ), a pharmaceutical and medical technology company, from 2007 through 2014, and at Merck & Co., Inc. (NYSE: MRK), a pharmaceutical company, from 1998 through 2006, in vario roles leading commercial strategy across all stages of product development. Mr. Frohlich serves on the board of directors of Nested Therapeutics and Borealis Biosciences. Mr. Frohlich received a B.Sc. in Biochemistry from the University of Victoria and an M.B.A. from the University of Oxford.
- Tomas Kiselak
-
Tomas Kiselak自2024年7月起担任董事会成员。Kiselak先生是Fairmount Funds Management LLC的管理成员，这是一家与他于2016年4月共同创立的医疗保健投资公司。在加入Fairmount之前，Kiselak先生是RA Capital Management，LLC的董事总经理，该公司是一家医疗保健和生命科学投资公司。Kiselak先生担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，以及Apogee Therapeutics，Inc.（纳斯达克：APGE）、Spyre Therapeutics，Inc.（纳斯达克：SYRE）和Zenas BioPharma，Inc.（纳斯达克：ZBIO）的董事会成员。Kiselak先生还担任多家私营公司的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。
Tomas Kiselak has served as a member of Board since July 2024. Mr. Kiselak is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and as a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Spyre Therapeutics, Inc. (Nasdaq: SYRE) and Zenas BioPharma, Inc. (Nasdaq: ZBIO). Mr. Kiselak also serves as a director for several private companies. He received a B.S. in Neuroscience and Economics from Amherst College. - Tomas Kiselak自2024年7月起担任董事会成员。Kiselak先生是Fairmount Funds Management LLC的管理成员，这是一家与他于2016年4月共同创立的医疗保健投资公司。在加入Fairmount之前，Kiselak先生是RA Capital Management，LLC的董事总经理，该公司是一家医疗保健和生命科学投资公司。Kiselak先生担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，以及Apogee Therapeutics，Inc.（纳斯达克：APGE）、Spyre Therapeutics，Inc.（纳斯达克：SYRE）和Zenas BioPharma，Inc.（纳斯达克：ZBIO）的董事会成员。Kiselak先生还担任多家私营公司的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。
- Tomas Kiselak has served as a member of Board since July 2024. Mr. Kiselak is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and as a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Spyre Therapeutics, Inc. (Nasdaq: SYRE) and Zenas BioPharma, Inc. (Nasdaq: ZBIO). Mr. Kiselak also serves as a director for several private companies. He received a B.S. in Neuroscience and Economics from Amherst College.
- Lawrence Otto Klein
-
劳伦斯·奥托·克莱因自2024年7月起担任董事会成员。Klein博士自2024年8月起担任生物技术公司Oruka Therapeutics，Inc.（前身为ARCA BioPharma，Inc.）（纳斯达克：ORKA）（“Oruka”）的首席执行官和董事会成员，并自2024年2月起至2024年8月完成该公司与Oruka的BINCE合并期间担任一家前身为Oruka Therapeutics，Inc.的私营生物技术公司的首席执行官和董事会成员。从2023年1月到2024年2月，Klein博士是Versant Venture Management，LLC（“Versant”）的合伙人，该公司是一家医疗保健和生物技术风险投资公司。在加入Versant之前，Klein博士曾在生物制药公司CRISPR Therapeutics AG（纳斯达克：CRSP）担任多个职位，包括2020年1月至2022年10月的首席运营官、2019年1月至2020年1月的首席BINSER官、2017年11月至2018年12月的BINSER发展和战略高级副总裁以及2016年2月至2017年11月的战略副总裁。在加入CRISPR之前，Klein博士曾于2014年10月至2016年2月在全球管理咨询公司麦肯锡公司担任副合伙人。Klein博士于2019年9月至2023年5月担任Dyne Therapeutics, Inc.（纳斯达克：DYN）的董事会成员，并于2021年9月至2023年6月担任Jasper Therapeutics, Inc.（纳斯达克：JSPR）的董事会成员。Klein博士在威斯康星大学麦迪逊分校获得生物化学和物理学学士学位，在斯坦福大学获得生物物理学博士学位。
Lawrence Otto Klein has served as a member of Board since July 2024. Dr. Klein has served as Chief Executive Officer and as a member of the board of directors of Oruka Therapeutics, Inc. (formerly known as ARCA biopharma, Inc.) (Nasdaq: ORKA) ("Oruka"), a biotechnology company, since August 2024, and served as Chief Executive Officer and as a member of the board of directors of a private biotechnology company formerly known as Oruka Therapeutics, Inc. from February 2024 through the completion of the company's biness combination with Oruka in August 2024. From January 2023 to February 2024, Dr. Klein was a Partner at Versant Venture Management, LLC ("Versant"), a healthcare and biotechnology venture capital firm. Prior to Versant, Dr. Klein served in vario positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January 2020 to October 2022, Chief Biness Officer from January 2019 to January 2020, Senior Vice President, Biness Development and Strategy from November 2017 to December 2018 and as Vice President, Strategy from February 2016 to November 2017. Before joining CRISPR, Dr. Klein was an Associate Partner at McKinsey & Company, a global management consulting firm, from October 2014 to February 2016. Dr. Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September 2019 to May 2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September 2021 to June 2023. Dr. Klein received his B.S. in Biochemistry and Physics from the University of Wisconsin Madison and his Ph.D. in Biophysics from Stanford University. - 劳伦斯·奥托·克莱因自2024年7月起担任董事会成员。Klein博士自2024年8月起担任生物技术公司Oruka Therapeutics，Inc.（前身为ARCA BioPharma，Inc.）（纳斯达克：ORKA）（“Oruka”）的首席执行官和董事会成员，并自2024年2月起至2024年8月完成该公司与Oruka的BINCE合并期间担任一家前身为Oruka Therapeutics，Inc.的私营生物技术公司的首席执行官和董事会成员。从2023年1月到2024年2月，Klein博士是Versant Venture Management，LLC（“Versant”）的合伙人，该公司是一家医疗保健和生物技术风险投资公司。在加入Versant之前，Klein博士曾在生物制药公司CRISPR Therapeutics AG（纳斯达克：CRSP）担任多个职位，包括2020年1月至2022年10月的首席运营官、2019年1月至2020年1月的首席BINSER官、2017年11月至2018年12月的BINSER发展和战略高级副总裁以及2016年2月至2017年11月的战略副总裁。在加入CRISPR之前，Klein博士曾于2014年10月至2016年2月在全球管理咨询公司麦肯锡公司担任副合伙人。Klein博士于2019年9月至2023年5月担任Dyne Therapeutics, Inc.（纳斯达克：DYN）的董事会成员，并于2021年9月至2023年6月担任Jasper Therapeutics, Inc.（纳斯达克：JSPR）的董事会成员。Klein博士在威斯康星大学麦迪逊分校获得生物化学和物理学学士学位，在斯坦福大学获得生物物理学博士学位。
- Lawrence Otto Klein has served as a member of Board since July 2024. Dr. Klein has served as Chief Executive Officer and as a member of the board of directors of Oruka Therapeutics, Inc. (formerly known as ARCA biopharma, Inc.) (Nasdaq: ORKA) ("Oruka"), a biotechnology company, since August 2024, and served as Chief Executive Officer and as a member of the board of directors of a private biotechnology company formerly known as Oruka Therapeutics, Inc. from February 2024 through the completion of the company's biness combination with Oruka in August 2024. From January 2023 to February 2024, Dr. Klein was a Partner at Versant Venture Management, LLC ("Versant"), a healthcare and biotechnology venture capital firm. Prior to Versant, Dr. Klein served in vario positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January 2020 to October 2022, Chief Biness Officer from January 2019 to January 2020, Senior Vice President, Biness Development and Strategy from November 2017 to December 2018 and as Vice President, Strategy from February 2016 to November 2017. Before joining CRISPR, Dr. Klein was an Associate Partner at McKinsey & Company, a global management consulting firm, from October 2014 to February 2016. Dr. Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September 2019 to May 2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September 2021 to June 2023. Dr. Klein received his B.S. in Biochemistry and Physics from the University of Wisconsin Madison and his Ph.D. in Biophysics from Stanford University.
- Eric L. Dobmeier
-
Eric L. Dobmeier，自2012年4月以来，是本公司的一位董事会成员。目前是Seattle Genetics股份有限公司的一位董事会成员。在这个职位上，他负责Seattle Genetics的商业开发、制造、企业传播、法律和项目以及联盟管理职能部门。于2002年3月加入Seattle Genetics的他，在那以后受过多次提升，最后的一次是2007年5月-2011年6月期间，担任首席商务官。在加入Seattle Genetics之前，他曾在律师事务所Venture Law Group和Heller Ehrman LLP工作，在一些公共和私有的融资、并购和企业合作交易中代表一些科技公司。他是从加州大学（University of California）伯克利法学院（Berkeley School of Law）获得他的法学博士学位，以及从普林斯顿大学（Princeton University）获得他的历史学士学位的。
Eric L. Dobmeier has served as a member of Board since October 2024. Mr. Dobmeier has served as a Venture Partner at Samsara BioCapital, LP, a biotherapeutics foced venture capital fund, since May 2024. From April 2019 to September 2023, Mr. Dobmeier served as President and Chief Executive Officer at Chinook Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Novartis AG in August 2023. Prior to that role, during 2018, Mr. Dobmeier served as President and Chief Executive Officer at Silverback Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that merged with ARS Pharmaceuticals, Inc. in 2022. From 2002 to 2017, Mr. Dobmeier held positions of increasing responsibility at Seagen, Inc., a Nasdaq listed biotechnology company that was acquired by Pfizer, Inc. in 2023, most recently serving as Chief Operating Officer. Mr. Dobmeier currently serves as a member of the board of directors of Janux Therapeutics, Inc. (Nasdaq: JANX) and Structure Therapeutics, Inc. (Nasdaq: GPCR), and previoly served as a member of the board of directors of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) from March 2015 to June 2024 and Adaptive Biotechnologies (Nasdaq: ADPT) from September 2016 to March 2021. Mr. Dobmeier received his A.B. in History from Princeton University and his J.D. from the University of California, Berkeley School of Law. - Eric L. Dobmeier，自2012年4月以来，是本公司的一位董事会成员。目前是Seattle Genetics股份有限公司的一位董事会成员。在这个职位上，他负责Seattle Genetics的商业开发、制造、企业传播、法律和项目以及联盟管理职能部门。于2002年3月加入Seattle Genetics的他，在那以后受过多次提升，最后的一次是2007年5月-2011年6月期间，担任首席商务官。在加入Seattle Genetics之前，他曾在律师事务所Venture Law Group和Heller Ehrman LLP工作，在一些公共和私有的融资、并购和企业合作交易中代表一些科技公司。他是从加州大学（University of California）伯克利法学院（Berkeley School of Law）获得他的法学博士学位，以及从普林斯顿大学（Princeton University）获得他的历史学士学位的。
- Eric L. Dobmeier has served as a member of Board since October 2024. Mr. Dobmeier has served as a Venture Partner at Samsara BioCapital, LP, a biotherapeutics foced venture capital fund, since May 2024. From April 2019 to September 2023, Mr. Dobmeier served as President and Chief Executive Officer at Chinook Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Novartis AG in August 2023. Prior to that role, during 2018, Mr. Dobmeier served as President and Chief Executive Officer at Silverback Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that merged with ARS Pharmaceuticals, Inc. in 2022. From 2002 to 2017, Mr. Dobmeier held positions of increasing responsibility at Seagen, Inc., a Nasdaq listed biotechnology company that was acquired by Pfizer, Inc. in 2023, most recently serving as Chief Operating Officer. Mr. Dobmeier currently serves as a member of the board of directors of Janux Therapeutics, Inc. (Nasdaq: JANX) and Structure Therapeutics, Inc. (Nasdaq: GPCR), and previoly served as a member of the board of directors of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) from March 2015 to June 2024 and Adaptive Biotechnologies (Nasdaq: ADPT) from September 2016 to March 2021. Mr. Dobmeier received his A.B. in History from Princeton University and his J.D. from the University of California, Berkeley School of Law.
高管简历
中英对照 | 中文 | 英文- Bradford Dahms
Bradford Dahms，从2024年3月到2025年2月被GSK plc收购，曾担任私营生物技术公司IDRX，Inc.的首席财务官和首席商务官，负责监督公司的财务运营、投资者关系和业务发展职能。他还曾于2021年5月在纳斯达克上市的生物技术公司Theseus Pharmaceuticals, Inc.担任首席财务官，直至2024年2月被Concentra Biosciences，LLC收购。在此期间，他领导了公司的财务运营、投资者关系和业务发展职能，并在2023年12月至2024年2月期间担任总裁和董事。2019年9月至2021年5月，Dahms先生在纳斯达克上市的生物技术公司Selecta生物科学 Inc.担任首席财务官，负责财务运营、投资者关系和业务发展。在此之前，Dahms先生曾于2014年4月至2019年8月在投资银行Cantor Fitzgerald & Co.担任医疗保健投资银行高级副总裁。他还曾于2012年至2014年在加拿大皇家银行资本市场担任分析师，并于2010年至2012年在摩根大通公司担任分析师。Dahms先生以优异成绩获得俄亥俄州立大学经济学理学学士学位。
Bradford Dahms has served as Chief Financial Officer and Treasurer since July 2025. Prior to joining the Company, he served as Chief Financial Officer and Chief Biness Officer of IDRx, Inc., a private biotechnology company, from March 2024 until its acquisition by GSK plc in February 2025, where he oversaw the company's financial operations, investor relations and biness development functions. He also served as Chief Financial Officer of These Pharmaceuticals, Inc., a Nasdaq listed biotechnology company, from May 2021 until it was acquired by Concentra Biosciences, LLC in February 2024. While there, he led the company's financial operations, investor relations and biness development functions and also served as President and a director from December 2023 to February 2024. From September 2019 to May 2021, Mr. Dahms served as Chief Financial Officer of Selecta Biosciences Inc., a Nasdaq listed biotechnology company, where he was responsible for financial operations, investor relations and biness development. Prior to that, Mr. Dahms served as Senior Vice President – Healthcare Investment Banking at Cantor Fitzgerald & Co., an investment bank, from April 2014 to Augt 2019. He also served as an analyst at RBC Capital Markets from 2012 to 2014, and at JPMorgan Chase & Co. from 2010 to 2012. Mr. Dahms holds a Bachelor of Science degree in Economics, with honors, from The Ohio State University.- Bradford Dahms，从2024年3月到2025年2月被GSK plc收购，曾担任私营生物技术公司IDRX，Inc.的首席财务官和首席商务官，负责监督公司的财务运营、投资者关系和业务发展职能。他还曾于2021年5月在纳斯达克上市的生物技术公司Theseus Pharmaceuticals, Inc.担任首席财务官，直至2024年2月被Concentra Biosciences，LLC收购。在此期间，他领导了公司的财务运营、投资者关系和业务发展职能，并在2023年12月至2024年2月期间担任总裁和董事。2019年9月至2021年5月，Dahms先生在纳斯达克上市的生物技术公司Selecta生物科学 Inc.担任首席财务官，负责财务运营、投资者关系和业务发展。在此之前，Dahms先生曾于2014年4月至2019年8月在投资银行Cantor Fitzgerald & Co.担任医疗保健投资银行高级副总裁。他还曾于2012年至2014年在加拿大皇家银行资本市场担任分析师，并于2010年至2012年在摩根大通公司担任分析师。Dahms先生以优异成绩获得俄亥俄州立大学经济学理学学士学位。
- Bradford Dahms has served as Chief Financial Officer and Treasurer since July 2025. Prior to joining the Company, he served as Chief Financial Officer and Chief Biness Officer of IDRx, Inc., a private biotechnology company, from March 2024 until its acquisition by GSK plc in February 2025, where he oversaw the company's financial operations, investor relations and biness development functions. He also served as Chief Financial Officer of These Pharmaceuticals, Inc., a Nasdaq listed biotechnology company, from May 2021 until it was acquired by Concentra Biosciences, LLC in February 2024. While there, he led the company's financial operations, investor relations and biness development functions and also served as President and a director from December 2023 to February 2024. From September 2019 to May 2021, Mr. Dahms served as Chief Financial Officer of Selecta Biosciences Inc., a Nasdaq listed biotechnology company, where he was responsible for financial operations, investor relations and biness development. Prior to that, Mr. Dahms served as Senior Vice President – Healthcare Investment Banking at Cantor Fitzgerald & Co., an investment bank, from April 2014 to Augt 2019. He also served as an analyst at RBC Capital Markets from 2012 to 2014, and at JPMorgan Chase & Co. from 2010 to 2012. Mr. Dahms holds a Bachelor of Science degree in Economics, with honors, from The Ohio State University.
- Tom Frohlich
Tom Frohlich自2024年10月起担任首席执行官和董事会成员。从2021年6月至2023年10月，Frohlich先生担任首席运营官，并于2019年1月至2021年6月在Chinook Therapeutics, Inc.担任首席必利官，该公司是一家在纳斯达克上市的生物制药公司，于2023年8月被诺华公司收购，负责战略、必利客开发、商业规划、化学、制造和控制、质量和项目管理。从2018年4月到2023年10月，Frohlich先生还在医疗保健投资公司Versant Ventures担任运营负责人，随后担任常驻企业家，负责公司创建和尽职调查。2018年4月至2018年12月，Frohlich先生在Inception Sciences，Inc.担任Biness Development高级副总裁，Inception Sciences，Inc.是一家与Versant Ventures共同创立的药物发现引擎。在加入Inception Sciences之前，2014年至2018年，Frohlich先生在生物制药公司Arbut Biopharma（前身为Tekmira Pharmaceuticals）（纳斯达克：AB）担任越来越重要的职务，最近一次是在2016年至2018年担任必宁发展副总裁。在加入Arbut Biopharma之前，Frohlich先生于2007年至2014年在制药和医疗技术公司强生（NYSE：JNJ）从事国际工作，并于1998年至2006年在制药公司默克制药公司（NYSE：MRK）从事领导产品开发各个阶段的商业战略的各种职务。Frohlich先生担任Nested Therapeutics和Borealis Biosciences的董事会成员。Frohlich先生获得维多利亚大学生物化学学士学位和牛津大学工商管理硕士学位。
Tom Frohlich has served as Chief Executive Officer and as a member of Board since October 2024. From June 2021 to October 2023, Mr. Frohlich served as Chief Operating Officer and, from January 2019 to June 2021, as Chief Biness Officer at Chinook Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Novartis AG in Augt 2023, where he was responsible for strategy, biness development, commercial planning, chemistry, manufacturing and controls, quality and program management. From April 2018 to October 2023, Mr. Frohlich also served as an Operating Principal and subsequently as an Entrepreneur in Residence at Versant Ventures, a healthcare investment firm, where he was responsible for company creation and due diligence. From April 2018 to December 2018, Mr. Frohlich served as the Senior Vice President of Biness Development at Inception Sciences, Inc., a drug discovery engine co founded with Versant Ventures. Prior to joining Inception Sciences, from 2014 to 2018, Mr. Frohlich held positions of increasing responsibility at Arbut Biopharma (formerly Tekmira Pharmaceuticals) (Nasdaq: AB), a biopharmaceutical company, most recently as Vice President of Biness Development from 2016 through 2018. Prior to joining Arbut Biopharma, Mr. Frohlich worked internationally at Johnson & Johnson (NYSE: JNJ), a pharmaceutical and medical technology company, from 2007 through 2014, and at Merck & Co., Inc. (NYSE: MRK), a pharmaceutical company, from 1998 through 2006, in vario roles leading commercial strategy across all stages of product development. Mr. Frohlich serves on the board of directors of Nested Therapeutics and Borealis Biosciences. Mr. Frohlich received a B.Sc. in Biochemistry from the University of Victoria and an M.B.A. from the University of Oxford.- Tom Frohlich自2024年10月起担任首席执行官和董事会成员。从2021年6月至2023年10月，Frohlich先生担任首席运营官，并于2019年1月至2021年6月在Chinook Therapeutics, Inc.担任首席必利官，该公司是一家在纳斯达克上市的生物制药公司，于2023年8月被诺华公司收购，负责战略、必利客开发、商业规划、化学、制造和控制、质量和项目管理。从2018年4月到2023年10月，Frohlich先生还在医疗保健投资公司Versant Ventures担任运营负责人，随后担任常驻企业家，负责公司创建和尽职调查。2018年4月至2018年12月，Frohlich先生在Inception Sciences，Inc.担任Biness Development高级副总裁，Inception Sciences，Inc.是一家与Versant Ventures共同创立的药物发现引擎。在加入Inception Sciences之前，2014年至2018年，Frohlich先生在生物制药公司Arbut Biopharma（前身为Tekmira Pharmaceuticals）（纳斯达克：AB）担任越来越重要的职务，最近一次是在2016年至2018年担任必宁发展副总裁。在加入Arbut Biopharma之前，Frohlich先生于2007年至2014年在制药和医疗技术公司强生（NYSE：JNJ）从事国际工作，并于1998年至2006年在制药公司默克制药公司（NYSE：MRK）从事领导产品开发各个阶段的商业战略的各种职务。Frohlich先生担任Nested Therapeutics和Borealis Biosciences的董事会成员。Frohlich先生获得维多利亚大学生物化学学士学位和牛津大学工商管理硕士学位。
- Tom Frohlich has served as Chief Executive Officer and as a member of Board since October 2024. From June 2021 to October 2023, Mr. Frohlich served as Chief Operating Officer and, from January 2019 to June 2021, as Chief Biness Officer at Chinook Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Novartis AG in Augt 2023, where he was responsible for strategy, biness development, commercial planning, chemistry, manufacturing and controls, quality and program management. From April 2018 to October 2023, Mr. Frohlich also served as an Operating Principal and subsequently as an Entrepreneur in Residence at Versant Ventures, a healthcare investment firm, where he was responsible for company creation and due diligence. From April 2018 to December 2018, Mr. Frohlich served as the Senior Vice President of Biness Development at Inception Sciences, Inc., a drug discovery engine co founded with Versant Ventures. Prior to joining Inception Sciences, from 2014 to 2018, Mr. Frohlich held positions of increasing responsibility at Arbut Biopharma (formerly Tekmira Pharmaceuticals) (Nasdaq: AB), a biopharmaceutical company, most recently as Vice President of Biness Development from 2016 through 2018. Prior to joining Arbut Biopharma, Mr. Frohlich worked internationally at Johnson & Johnson (NYSE: JNJ), a pharmaceutical and medical technology company, from 2007 through 2014, and at Merck & Co., Inc. (NYSE: MRK), a pharmaceutical company, from 1998 through 2006, in vario roles leading commercial strategy across all stages of product development. Mr. Frohlich serves on the board of directors of Nested Therapeutics and Borealis Biosciences. Mr. Frohlich received a B.Sc. in Biochemistry from the University of Victoria and an M.B.A. from the University of Oxford.
- Andrew James King
Andrew James King自2024年8月起担任首席科学官兼研发主管。从2021年6月至2023年10月，King博士担任首席科学官，并于2019年5月至2021年6月，在Chinook Therapeutics, Inc.担任肾脏发现和转化医学负责人，该公司是一家在2023年8月被诺华制药集团收购的在纳斯达克上市的生物制药公司，负责监督发现研究、非临床开发、转化医学和早期临床开发团队，并作为开发审评委员会主席或共同主席以及公司全球3期临床试验指导委员会的保荐代表，领导后期临床开发战略。在加入Chinook之前，King博士曾在私营生物技术公司BIOAGE Labs担任Discovery执行副总裁，在生物技术公司Ardelyx, Inc.（纳斯达克：ARDX）担任Discovery和转化生物学高级总监，在那里他专注于提供用于治疗心源性肾脏疾病的小分子候选药物。在加入Ardelyx, Inc.之前，King博士是艾伯维公司（纽约证券交易所代码：ABBV）的首席研究科学家，在雅培（纽约证券交易所代码：ABT）担任越来越重要的职务后，他领导了肾脏发现科学战略，以治疗慢性肾病。
Andrew James King has served as Chief Scientific Officer & Head of Research and Development since August 2024. From June 2021 to October 2023, Dr. King served as Chief Scientific Officer and, from May 2019 to June 2021, as Head of Renal Discovery and Translational Medicine at Chinook Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Novartis AG in August 2023, where he was responsible for overseeing the discovery research, non clinical development, translational medicine and early clinical development teams, and led late stage clinical development strategy as chair or co chair of the development review committee and as a sponsor representative on the company's global Phase 3 clinical trial steering committees. Prior to joining Chinook, Dr. King served as the Executive Vice President of Discovery at BIOAGE Labs, a private biotechnology company and as the Senior Director of Discovery and Translational Biology at Ardelyx, Inc. (Nasdaq: ARDX), a biotechnology company, where he foced on delivering small molecule candidates for the treatment of cardio renal diseases. Prior to Ardelyx, Inc., Dr. King was a Principal Research Scientist at AbbVie Inc. (NYSE: ABBV), where he led the Renal Discovery scientific strategy to treat chronic kidney disease after serving in positions of increasing responsibility at Abbott Laboratories (NYSE: ABT).- Andrew James King自2024年8月起担任首席科学官兼研发主管。从2021年6月至2023年10月，King博士担任首席科学官，并于2019年5月至2021年6月，在Chinook Therapeutics, Inc.担任肾脏发现和转化医学负责人，该公司是一家在2023年8月被诺华制药集团收购的在纳斯达克上市的生物制药公司，负责监督发现研究、非临床开发、转化医学和早期临床开发团队，并作为开发审评委员会主席或共同主席以及公司全球3期临床试验指导委员会的保荐代表，领导后期临床开发战略。在加入Chinook之前，King博士曾在私营生物技术公司BIOAGE Labs担任Discovery执行副总裁，在生物技术公司Ardelyx, Inc.（纳斯达克：ARDX）担任Discovery和转化生物学高级总监，在那里他专注于提供用于治疗心源性肾脏疾病的小分子候选药物。在加入Ardelyx, Inc.之前，King博士是艾伯维公司（纽约证券交易所代码：ABBV）的首席研究科学家，在雅培（纽约证券交易所代码：ABT）担任越来越重要的职务后，他领导了肾脏发现科学战略，以治疗慢性肾病。
- Andrew James King has served as Chief Scientific Officer & Head of Research and Development since August 2024. From June 2021 to October 2023, Dr. King served as Chief Scientific Officer and, from May 2019 to June 2021, as Head of Renal Discovery and Translational Medicine at Chinook Therapeutics, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Novartis AG in August 2023, where he was responsible for overseeing the discovery research, non clinical development, translational medicine and early clinical development teams, and led late stage clinical development strategy as chair or co chair of the development review committee and as a sponsor representative on the company's global Phase 3 clinical trial steering committees. Prior to joining Chinook, Dr. King served as the Executive Vice President of Discovery at BIOAGE Labs, a private biotechnology company and as the Senior Director of Discovery and Translational Biology at Ardelyx, Inc. (Nasdaq: ARDX), a biotechnology company, where he foced on delivering small molecule candidates for the treatment of cardio renal diseases. Prior to Ardelyx, Inc., Dr. King was a Principal Research Scientist at AbbVie Inc. (NYSE: ABBV), where he led the Renal Discovery scientific strategy to treat chronic kidney disease after serving in positions of increasing responsibility at Abbott Laboratories (NYSE: ABT).
- Elizabeth Balta
Elizabeth Balta自2024年10月起担任总法律顾问和公司秘书。从2021年9月到2024年3月，Balta女士担任Icosavax, Inc.的总法律顾问，这是一家在纳斯达克上市的生物技术公司，于2024年2月被阿斯利康 PLC收购，在那里她领导法律事务职能，负责监督公司、交易、知识产权和合规事务。2016年3月至2021年9月，Balta女士担任Seagen，Inc.的副总法律顾问，该公司是一家在纳斯达克上市的生物技术公司，于2023年被Seagen，Inc.收购，负责领导公司法职能，负责公司治理、证券法合规、公司融资和支持TERM3在欧洲的商业扩张。在加入Seagen之前，Balta女士曾在Oncothyreon（纳斯达克：ONTY）担任多个责任日益增加的法律职务，该公司随后更名为Seagen，并于2018年被TERM3收购，Emergent BioSolutions（NYSE：EBS）和Trubion Pharmaceuticals（TERM0纳斯达克：TRBN），后者于2010年10月被Emergent BioSolutions收购。巴尔塔女士获得了斯坦福大学人类生物学学士学位和哈佛法学院法学博士学位。
Elizabeth Balta has served as General Counsel and Corporate Secretary since October 2024. From September 2021 to March 2024, Ms. Balta served as General Counsel of Icosavax, Inc., a Nasdaq listed biotechnology company that was acquired by AstraZeneca plc in February 2024, where she led the Legal Affairs function overseeing corporate, transactional, intellectual property and compliance matters. From March 2016 to September 2021, Ms. Balta served as Associate General Counsel of Seagen, Inc., a Nasdaq listed biotechnology company that was acquired by Pfizer, Inc. in 2023, where she led the Corporate Law function with responsibility for corporate governance, securities law compliance, corporate financings and support of Seagen's commercial expansion in Europe. Prior to Seagen, Ms. Balta served in vario legal roles of increasing responsibility at Oncothyreon (Nasdaq: ONTY), which subsequently was renamed Cascadian Therapeutics and was acquired by Seagen in 2018, Emergent Biosolutions (NYSE: EBS) and Trubion Pharmaceuticals (Nasdaq: TRBN), which was acquired by Emergent Biosolutions in October 2010. Ms. Balta received her B.A. in Human Biology from Stanford University and her J.D. from Harvard Law School.- Elizabeth Balta自2024年10月起担任总法律顾问和公司秘书。从2021年9月到2024年3月，Balta女士担任Icosavax, Inc.的总法律顾问，这是一家在纳斯达克上市的生物技术公司，于2024年2月被阿斯利康 PLC收购，在那里她领导法律事务职能，负责监督公司、交易、知识产权和合规事务。2016年3月至2021年9月，Balta女士担任Seagen，Inc.的副总法律顾问，该公司是一家在纳斯达克上市的生物技术公司，于2023年被Seagen，Inc.收购，负责领导公司法职能，负责公司治理、证券法合规、公司融资和支持TERM3在欧洲的商业扩张。在加入Seagen之前，Balta女士曾在Oncothyreon（纳斯达克：ONTY）担任多个责任日益增加的法律职务，该公司随后更名为Seagen，并于2018年被TERM3收购，Emergent BioSolutions（NYSE：EBS）和Trubion Pharmaceuticals（TERM0纳斯达克：TRBN），后者于2010年10月被Emergent BioSolutions收购。巴尔塔女士获得了斯坦福大学人类生物学学士学位和哈佛法学院法学博士学位。
- Elizabeth Balta has served as General Counsel and Corporate Secretary since October 2024. From September 2021 to March 2024, Ms. Balta served as General Counsel of Icosavax, Inc., a Nasdaq listed biotechnology company that was acquired by AstraZeneca plc in February 2024, where she led the Legal Affairs function overseeing corporate, transactional, intellectual property and compliance matters. From March 2016 to September 2021, Ms. Balta served as Associate General Counsel of Seagen, Inc., a Nasdaq listed biotechnology company that was acquired by Pfizer, Inc. in 2023, where she led the Corporate Law function with responsibility for corporate governance, securities law compliance, corporate financings and support of Seagen's commercial expansion in Europe. Prior to Seagen, Ms. Balta served in vario legal roles of increasing responsibility at Oncothyreon (Nasdaq: ONTY), which subsequently was renamed Cascadian Therapeutics and was acquired by Seagen in 2018, Emergent Biosolutions (NYSE: EBS) and Trubion Pharmaceuticals (Nasdaq: TRBN), which was acquired by Emergent Biosolutions in October 2010. Ms. Balta received her B.A. in Human Biology from Stanford University and her J.D. from Harvard Law School.